Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04452214
Other study ID # CAN04CLIN002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 24, 2020
Est. completion date June 28, 2023

Study information

Verified date July 2023
Source Cantargia AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab (Part 1), and in combination with pembrolizumab standard dose, and Standard of Care carboplatin and pemetrexed (Part 2 - subjects with stage IV, non-squamous metastatic NSCLC). CAN04, pembrolizumab. carboplatin and pemetrexed will be administered intravenously.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date June 28, 2023
Est. primary completion date June 28, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria (Part 1): - Subjects with metastatic or locally advanced, incurable non-small-cell lung cancer (NSCLC [adenocarcinoma, adenosquamous, or squamous]), head and neck squamous cell carcinoma (HNSCC), urothelial cancer, or malignant melanoma who have exhausted or declined available standard therapy. - Subjects progressing on previous treatment with a checkpoint inhibitor targeting thePD-1/PD-L1 pathway, alone or in combination with chemotherapy after previously having achieved stable disease or better and stayed on such therapy for =12 weeks. - Primary or metastatic lesion suitable for biopsy and willingness to undergo repeat biopsies as appropriate. - Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing. Inclusion Criteria (Part 2): - Subjects with histologically confirmed non-squamous metastatic (stage IV) NSCLC, without option for locoregional treatment with curative intent. - Subjects who have not received prior systemic anti-cancer therapy for the locally advanced or metastatic NSCLC. Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease. - Ability to safety undergo pre-treatment (if no archival biopsy is available) and on-treatment tumor biopsies. - Subject consents to retrieval of archival tumor tissue for screening in case no fresh biopsy is performed during screening. - Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing. Exclusion Criteria (Parts 1 and 2): - Subjects with NSCLC tumors with genetic alteration or mutation, for which FDA-approved targeted therapy is available. - Treatment with systemic anticancer treatments, investigational products, or major surgery within 4 weeks before first dose of study drug or 5 half-lives, whichever is shorter. Subjects should have recovered from previous treatment toxicity (except hair loss and peripheral neuropathy). - History of uncontrolled brain metastasis. - Subject has received extended field radiotherapy =4 weeks before the start of treatment (=2 weeks for limited field radiation to alleviate symptoms), and who has not recovered from related side effects of such therapy (except for hair loss). - Subjects who have previously experienced an immune-related adverse event (irAE) to pembrolizumab, for which permanent discontinuation is required. Subjects without a formal contraindication due to previous irAE are not eligible if the AE has not resolved or requires steroids (>10 mg prednisone-equivalent per day) for ongoing management. - Subjects with active severe infection requiring oral antibiotics. - Clinical evidence of an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting. - Uncontrolled or significant cardiovascular disease. - History of autoimmune disease requiring systemic immunosuppressive therapy (daily prednisone equivalent doses >10 mg/day). - HIV patients can be enrolled if the infection is adequately controlled. - Known bleeding disorder or coagulopathy. Subjects on stable anticoagulant therapy are allowed. - Known or suspected allergy to study treatment or related products. - Women who are pregnant or breastfeeding, or trying to become pregnant. - Patients with chronic viral hepatitis. Exclusion criteria (Part 2): - Previous therapy with immunotherapy (anti-PD-1, anti-PD-L1, and anti-PD-L2, anti-CTLA-4, or other approved or investigational checkpoint-inhibitors). - Subject is unable or unwilling to take folic acid or vitamin B12 supplementation. - Subject is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDS), other than an aspirin dose = 1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam). Other protocol-defined inclusion/exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CAN04
Administered intravenously
Pembrolizumab
Administered intravenously
Carboplatin
Administered intravenously
Pemetrexed
Administered intravenously

Locations

Country Name City State
United States University of Colorado Cancer Center Aurora Colorado
United States Florida Cancer Specialists & Research Institute Lake Mary Florida
United States Hospital of The University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Cantargia AB

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of TEAEs (treatment-emergent adverse events) (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Frequency of TEAEs (treatment-emergent adverse events) (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Number of participants with DLTs (dose-limiting toxicities) (Part 1) Up to day 28
Primary Number of participants with DLTs (dose-limiting toxicities) (Part 2) Up to day 28
Primary Number of subjects with grade =3 TEAEs (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Number of subjects with grade =3 TEAEs (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Percentage of subjects with grade =3 TEAEs (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Percentage of subjects with grade =3 TEAEs (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Number of subjects with 1 or more SAEs (serious adverse events) (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Number of subjects with 1 or more SAEs (serious adverse events) (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Percentage of subjects with 1 or more SAEs (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Percentage of subjects with 1 or more SAEs (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Number of subjects with 1 or more TEAEs leading to dose modifications (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Number of subjects with 1 or more TEAEs leading to dose modifications (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Number of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Number of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Percentage of subjects with 1 or more TEAEs leading to dose modifications (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Percentage of subjects with 1 or more TEAEs leading to dose modifications (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Primary Percentage of subjects with 1 or more TEAEs leading to treatment discontinuation (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Serum concentrations of CAN04 and pembrolizumab (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Serum concentrations of CAN04 and pembrolizumab (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Antidrug antibodies (ADAs) against CAN04 From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Change in serum IL-6 (interleukin-6) concentration (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Change in serum IL-6 (interleukin-6) concentration (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Change in serum CRP (C-reactive protein) concentration (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Change in serum CRP (C-reactive protein) concentration (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Overall response rate (ORR) (Part 1) Proportion of subjects with partial response (PR) or complete response (CR) to study treatment as defined by iRECIST (immune-related response evaluation criteria in solid tumors) and measured by radiological assessment (CT/MRI scan) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Overall response rate (ORR) (Part 2) Proportion of subjects with partial response (PR) or complete response (CR) to study treatment as defined by iRECIST (immune-related response evaluation criteria in solid tumors) and measured by radiological assessment (CT/MRI scan) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Progression free survival (Part 1) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Progression free survival (Part 2) From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first
Secondary Overall survival (Part 1) Up to 36 months after 1st dose of last subject (or death)
Secondary Overall survival (Part 2) Up to 36 months after 1st dose of last subject (or death)
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Completed NCT04426825 - A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Phase 2
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT02810457 - Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer Phase 3
Completed NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) Phase 3
Recruiting NCT04592523 - A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Recruiting NCT04838548 - A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04077463 - A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer Phase 1
Recruiting NCT04603807 - A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Phase 3
Recruiting NCT05167604 - Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
Completed NCT04948411 - Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Active, not recruiting NCT04487080 - A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase 3
Not yet recruiting NCT04255836 - Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01953913 - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Phase 3
Recruiting NCT05715229 - Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy Phase 2
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Suspended NCT05421936 - Osimertinib for NSCLC With Uncommon EGFR Mutations
Completed NCT02847377 - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC N/A
Completed NCT04427072 - Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Phase 3
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A